Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy, Leukemia, vol.33, pp.2266-75, 2019. ,
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma, Nat Commun, vol.5, p.2997, 2014. ,
BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma, Clin Cancer Res, 2020. ,
Initial genome sequencing and analysis of multiple myeloma, Nature, vol.471, pp.467-72, 2011. ,
Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation, Oncotarget, vol.6, pp.24205-24222, 2015. ,
Targeting the BRAF V600E mutation in multiple myeloma, Cancer Discov, vol.3, pp.862-871, 2013. ,
CIC mutation as a molecular mechanism of acquired resistance to combined BRAF-MEK inhibition in extramedullary multiple myeloma with central nervous system involvement ,
, , 2019.
Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation, Hematol Oncol, vol.35, pp.890-893, 2017. ,
Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition, Blood, vol.127, pp.2155-2162, 2016. ,
Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma, Clin Lymphoma Myeloma Leuk, vol.14, pp.161-164, 2014. ,
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, N Engl J Med, vol.371, pp.1877-88, 2014. ,
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, vol.468, pp.973-980, 2010. ,
Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, vol.140, pp.209-230, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-02122069
,
Clinical significance of BRAF/NRAS concurrent mutations in a clinic-based metastatic melanoma cohort, Br J Dermatol, 2019. ,
KRAS/NRAS/BRAF mutations as potential targets in multiple myeloma, Front Oncol, vol.9, p.1137, 2019. ,
RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation ,
,